ReviewContributions to nephrology2011
Endothelin, nitric oxide, and reactive oxygen species in diabetic kidney disease.
Review in Contributions to nephrology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 21 citations in OpenAlex.
- Betaine Alters the Interplay of the Adenosine andInternational journal of molecular sciences · 2026Article
- Active role of amino acid metabolism in early diagnosis and treatment of diabetic kidney disease.Frontiers in nutrition · 2023Review
- Circadian Control of Sodium and Blood Pressure Regulation.American journal of hypertension · 2021Review
- Peroxiredoxin V (PrdxV) negatively regulates EGFR/Stat3-mediated fibrogenesis via a Cys48-dependent interaction between PrdxV and Stat3.Scientific reports · 2019Article
- AKF-PD alleviates diabetic nephropathy via blocking the RAGE/AGEs/NOX and PKC/NOX Pathways.Scientific reports · 2019Article
- The Warburg Effect in Diabetic Kidney Disease.Seminars in nephrology · 2018Review
- Heme oxygenase-1 is a potent inhibitor of placental ischemia-mediated endothelin-1 production in cultured human glomerular endothelial cells.American journal of physiology. Regulatory, integrative and comparative physiology · 2018Article
- Angeli's Salt, a nitroxyl anion donor, reverses endothelin-1 mediated vascular dysfunction in murine aorta.European journal of pharmacology · 2017Article
- Non-genetic mechanisms of diabetic nephropathy.Frontiers of medicine · 2017Review
- Obesity and Diabetic Kidney Disease: Role of Oxidant Stress and Redox Balance.Antioxidants & redox signaling · 2016Review
- Effects of diabetes on oxidative and nitrosative stress in kidney mitochondria from aged rats.Journal of bioenergetics and biomembranes · 2014Article
- TRPV4 activation mediates flow-induced nitric oxide production in the rat thick ascending limb.American journal of physiology. Renal physiology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The mechanism(s) of the endothelin (ET) and reactive oxygen species pathways in conjunction with the nitric oxide (NO) pathway that promote and/or blunt the progression of diabetic kidney disease have been the focus of many laboratories' efforts to reveal new therapeutic targets. In both animal models and patients with diabetic nephropathy, pharmacological blockade of ET receptors results in a significant reduction. However, edema has been documented as a persistent side effect. It is unclear whether selective ET(A) antagonists or nonselective ET(A/B) antagonists are preferred in diabetic conditions. We have proposed that ET(B) activates the NO pathway to blunt diabetes-induced nephropathy such that ET(A) selectivity should be more efficacious. The NO pathway in diabetes facilitates vascular dysfunction while in the renal tubular system, NO serves to blunt disease progression. NO synthase isoform activity is also critically regulated in diabetic kidney disease within the renal vascular and tubular systems through a complex interaction with reactive oxygen species. We will examine the complexities of the ET and NO pathways in diabetic kidney disease to propose novel mechanisms for future investigation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.